关于医生知识,态度和与医用大麻相关的做法的国际视角
Shariful A Syed1, Jatinder Singh2, Hussien Elkholy3
1Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States.
Frontiers in public health
|March 7, 2025
概括
医生对医用大麻的知识有限,尽管证据不足,但愿意推它却有所不同. 需要更多的教育来使实践与科学理解保持一致.
科学领域:
- 医学研究 医学研究
- 临床实践中的临床实践
- 公共卫生 公共卫生
背景情况:
- 在全球范围内,用于医疗和娱乐目的的大麻使用量正在增加.
- 目前,有限的科学证据支持大麻的医疗用途,人们越来越担心健康的负面影响.
- 在这个不断变化的环境中,医生对大麻治疗价值的态度至关重要.
研究的目的:
- 评估医生对医用大麻的知识,态度和临床实践.
- 为了确定医生愿意推医用大麻的预测因素.
- 描述国际上医生对医用大麻理解的现状.
主要方法:
- 在2016年至2018年期间,在来自17个国家的323名医生中进行了一项横截面调查.
- 该调查探讨了医生关于医用大麻使用的知识,态度和做法.
- 用描述性统计和回归分析来分析数据并确定推预测因素.
主要成果:
- 医生对医用大麻的经验和知识是有限的,51.4%从未建议使用,33%报告知识不足.
- 虽然大多数医生认识到诸如精神病 (84%) 等风险,但只有23%的医生正确地确定了日常使用的成风险.
- 对于化疗引起的恶心 (67%),神经病痛 (52%) 和ALS性 (51%) 的情况,推使用医用大麻的意愿最高.
结论:
- 在医生中,关于医用大麻的领域特定知识存在显著的差距.
- 医生愿意推医用大麻的情况各不相同,并不总是与当前科学证据的强度保持一致.
- 显然需要加强医疗教育,以提高医用大麻的专业知识,以改善临床决策.
相关概念视频
Drug Control Governance: Regulatory Bodies and Their Impact
134
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
134
Ethical Issues
840
Nurses are essential in patient care, upholding the ethical principles of their profession and effectively navigating ethical dilemmas. Neglecting ethical issues can lead to inadequate patient care, compromised therapeutic relationships, and moral distress among healthcare workers.
Ethical Concerns in Healthcare:
Ethical Concerns in Healthcare:
840
Drug Abuse and Addiction: Pharmacological Phenomena
420
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
420
Altered States of Awareness
145
Altered states of consciousness represent significant deviations from one's normal mental state. These deviations can range from subtle changes in awareness to profound transformations in perception, thought processes, and sensory experiences. Altered states of consciousness can be triggered by various factors, including drug use, meditation, hypnosis, illness, or even intense fatigue.
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
145
Analgesia and Pain Management
420
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
420
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
199
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
199


